HK42591A - Crystal modification of disodium-3-amino-1-hydroxy-propane-1,1-diphosphonate - Google Patents

Crystal modification of disodium-3-amino-1-hydroxy-propane-1,1-diphosphonate Download PDF

Info

Publication number
HK42591A
HK42591A HK425/91A HK42591A HK42591A HK 42591 A HK42591 A HK 42591A HK 425/91 A HK425/91 A HK 425/91A HK 42591 A HK42591 A HK 42591A HK 42591 A HK42591 A HK 42591A
Authority
HK
Hong Kong
Prior art keywords
amino
diphosphonate
disodium
hydroxypropane
water
Prior art date
Application number
HK425/91A
Other languages
German (de)
English (en)
French (fr)
Inventor
Peter Heinrich Dr. Stahl
Beat Dr. Schmitz
Original Assignee
Ciba-Geigy A.G.
Henkel Kommanditgesellschaft Auf Aktien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4263070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK42591(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba-Geigy A.G., Henkel Kommanditgesellschaft Auf Aktien filed Critical Ciba-Geigy A.G.
Publication of HK42591A publication Critical patent/HK42591A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK425/91A 1984-08-06 1991-05-30 Crystal modification of disodium-3-amino-1-hydroxy-propane-1,1-diphosphonate HK42591A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH376884 1984-08-06

Publications (1)

Publication Number Publication Date
HK42591A true HK42591A (en) 1991-06-07

Family

ID=4263070

Family Applications (1)

Application Number Title Priority Date Filing Date
HK425/91A HK42591A (en) 1984-08-06 1991-05-30 Crystal modification of disodium-3-amino-1-hydroxy-propane-1,1-diphosphonate

Country Status (26)

Country Link
US (2) US4639338A (instruction)
EP (1) EP0177443B1 (instruction)
JP (1) JPS6143196A (instruction)
KR (1) KR940000817B1 (instruction)
AR (4) AR240832A1 (instruction)
AT (1) ATE47396T1 (instruction)
AU (1) AU591066B2 (instruction)
CA (1) CA1255694A (instruction)
CY (1) CY1570A (instruction)
DD (1) DD239597A5 (instruction)
DE (1) DE3573783D1 (instruction)
DK (1) DK167282B1 (instruction)
DO (1) DOP1990004769A (instruction)
ES (2) ES8701188A1 (instruction)
FI (1) FI79712C (instruction)
GR (1) GR851910B (instruction)
HK (1) HK42591A (instruction)
HU (1) HU193124B (instruction)
IE (1) IE58077B1 (instruction)
IL (1) IL75990A (instruction)
MX (1) MX9203373A (instruction)
NO (1) NO165401C (instruction)
PH (1) PH24854A (instruction)
PT (1) PT80916B (instruction)
SG (1) SG91390G (instruction)
ZA (1) ZA855892B (instruction)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH664158A5 (fr) * 1984-07-18 1988-02-15 Symphar Sa Derives propylidenediphosphonates-1,3 substitues en position 2, leur procede de preparation et compositions pharmaceutiques les contenant.
DE3770982D1 (de) * 1986-04-24 1991-08-01 Fujisawa Pharmaceutical Co Diphosphonsaeure-verbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel.
US4963681A (en) * 1987-07-06 1990-10-16 Norwich Eaton Pharmaceuticals, Inc. Process for synthesis of aminomethylene phosphonoalkylphosphinates
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
IT1222734B (it) * 1987-09-25 1990-09-12 Scalvo S P A Formulaziopne farmaceutiche e forme di dosaggio per la somminaistarzione rettale di calcitonina
PH26923A (en) * 1989-03-08 1992-12-03 Ciba Geigy N-substituted amino alkanediphosphonic acids
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
TW237386B (instruction) 1992-04-15 1995-01-01 Ciba Geigy
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
JP3266395B2 (ja) * 1993-11-24 2002-03-18 富士写真フイルム株式会社 有機薬品の晶析方法
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
ES2231919T3 (es) * 1997-07-15 2005-05-16 Gador S.A. Forma cristalina de sal monosodica monohidrato del acido n,n-dimetil-3-amino-1-hidroxipropano-1,1-difosfonico.
EP1702924A3 (en) * 1998-08-27 2007-07-18 Teva Pharmaceutical Industries Ltd Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6281381B1 (en) * 1998-08-27 2001-08-28 Teva Pharmaceutical Industries Ltd. Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
DE69907258T2 (de) * 1998-12-10 2003-11-06 Aesgen, Inc. Verfahren zur herstellung von dinatriumpamidronat
US6160165A (en) 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6315566B1 (en) 1999-05-18 2001-11-13 3M Innovative Properties Company Dental materials
US6143919A (en) * 1999-05-18 2000-11-07 3M Innovative Properties Company Polymerizable acidic compounds and methods of preparation
US6963008B2 (en) * 1999-07-19 2005-11-08 Teva Pharmaceutical Industries Ltd. Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
ES2153794B1 (es) * 1999-08-06 2001-10-16 Medichem Sa Procedimiento para la obtencion del acido 4-amino-1-hidroxibutiliden-1,1-bisfosfonico y de su sal monosodica trihidratada.
KR100343232B1 (ko) * 1999-12-10 2002-07-10 김재윤 결정성 파미드론산 이나트륨염 수화물과 그의 제조방법
KR20030043931A (ko) * 2000-09-18 2003-06-02 에프. 에이취. 펄딩 앤드 컴파니 리미티드 디포스포네이트 용액
EP1372669B1 (en) * 2001-01-23 2005-06-15 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
CZ20032951A3 (cs) 2001-05-02 2004-02-18 Sicor Inc. Injikovatelný pamidronate disodium
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
ITMI20012751A1 (it) * 2001-12-21 2003-06-21 Lyogen Ltd Sale monosodico dell'acido pamidronico e procedimento per la sua preparazione
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
EP1465606A4 (en) * 2001-12-24 2009-04-22 Teva Pharma DOSAGE FORM WITH PASTILLE CORE ACTIVE PRINCIPLE COATED IN COMPRESSED ANNULAR BODY OF POWDER OR GRANULAR SUBSTANCE, AND METHOD AND TOOLS FOR PRODUCTION OF SAID DOSAGE FORM
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
AU2003250218B2 (en) * 2002-12-20 2006-10-26 F. Hoffmann-La Roche Ag High dose Ibandronate formulation
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
EP1689759B1 (en) * 2003-12-04 2016-07-13 Mustafa Nevzat Ilac Sanayii A.S. Method for producing pure disodium pamidronate
NZ551118A (en) 2004-05-24 2010-09-30 Warner Chilcott Co Llc Enteric solid oral dosage form of bisphosphonate containing a chelating agent
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US20100144679A1 (en) * 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
PL2473172T3 (pl) 2009-09-01 2015-08-31 Univ Duke Kompozycje bisfosfonianowe i sposoby do leczenia niewydolności serca
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
JP2013525294A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー インプラント骨結合を改善するための方法および組成物
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
RS57294B1 (sr) * 2012-05-14 2018-08-31 Antecip Bioventures Ii Llc Kompozicije koje obuhvataju zoledronsku kiselinu ili srodna jedinjenja za ublažavanje zapaljenskog bola i povezanih stanja
KR101995432B1 (ko) * 2016-10-13 2019-07-02 엘지전자 주식회사 공기조화기 및 그 제어방법
EP3553067A1 (en) * 2018-04-10 2019-10-16 Abiogen Pharma S.p.A. Polymorph of sodium neridronate and preparation process thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130794C3 (de) * 1971-06-22 1974-07-11 Joh. A. Benckiser Gmbh, 6700 Ludwigshafen Verfahren zur Herstellung von l-Hydroxy-S-amino-propan-ljl-diphosphonsäure
US4134969A (en) * 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
SE7612534L (sv) * 1975-12-01 1977-06-02 Henkel & Cie Gmbh Forfarande for framstellning av farmaceutiska preparat for behandling av storningar i kalciumemnesomsettning
DE2553963A1 (de) * 1975-12-01 1977-06-08 Henkel & Cie Gmbh Pharmazeutische praeparate zur behandlung von stoerungen des calciumstoffwechsels
JPS5283957A (en) * 1975-12-01 1977-07-13 Henkel & Cie Gmbh Medicine for treating metabolic obstruction of calcium
SE409706B (sv) * 1976-05-21 1979-09-03 Astra Pharma Prod Forfarande for framstellning av n,n-dimetyl-3-(4-bromfenyl)-3-3(3-pyridyl)-allylamin dihydroklorid monohydrat
DE2702631A1 (de) * 1977-01-22 1978-07-27 Henkel Kgaa Verfahren zur herstellung von 1-hydroxy-3-amino-propan-1,1-diphosphonsaeuren
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4304734A (en) * 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
DE3151038A1 (de) * 1981-12-23 1983-07-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von 3-amino-1-hydroxypropan-1,1-diphosphonsaeure
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
CH664158A5 (fr) * 1984-07-18 1988-02-15 Symphar Sa Derives propylidenediphosphonates-1,3 substitues en position 2, leur procede de preparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
DK355485D0 (da) 1985-08-05
IE58077B1 (en) 1993-06-30
ES555602A0 (es) 1987-07-01
CY1570A (en) 1991-12-20
KR940000817B1 (ko) 1994-02-02
PT80916A (en) 1985-09-01
FI79712B (fi) 1989-10-31
AR244698A1 (es) 1993-11-30
US4711880A (en) 1987-12-08
DK167282B1 (da) 1993-10-04
AR240832A1 (es) 1991-02-28
HU193124B (en) 1987-08-28
ATE47396T1 (de) 1989-11-15
KR860001821A (ko) 1986-03-22
ES8706707A1 (es) 1987-07-01
FI852986L (fi) 1986-02-07
PT80916B (pt) 1987-12-30
DK355485A (da) 1986-02-07
NO853087L (no) 1986-02-07
SG91390G (en) 1991-01-18
CA1255694A (en) 1989-06-13
AR240832A2 (es) 1991-02-28
AR244697A1 (es) 1993-11-30
DE3573783D1 (en) 1989-11-23
PH24854A (en) 1990-12-26
ES545899A0 (es) 1986-11-16
GR851910B (instruction) 1985-12-03
ZA855892B (en) 1986-03-26
AU591066B2 (en) 1989-11-30
MX9203373A (es) 1992-09-01
AU4577785A (en) 1986-02-13
IE851931L (en) 1986-02-06
ES8701188A1 (es) 1986-11-16
DD239597A5 (de) 1986-10-01
HUT38361A (en) 1986-05-28
NO165401B (no) 1990-10-29
NO165401C (no) 1991-02-06
AR244696A1 (es) 1993-11-30
JPS6143196A (ja) 1986-03-01
JPH058717B2 (instruction) 1993-02-02
US4639338A (en) 1987-01-27
IL75990A (en) 1989-07-31
FI852986A0 (fi) 1985-08-02
EP0177443A1 (de) 1986-04-09
DOP1990004769A (es) 1999-08-19
FI79712C (fi) 1990-02-12
EP0177443B1 (de) 1989-10-18

Similar Documents

Publication Publication Date Title
HK42591A (en) Crystal modification of disodium-3-amino-1-hydroxy-propane-1,1-diphosphonate
JP3635432B2 (ja) オメプラゾールマグネシウムの製法
CN1022324C (zh) 制备无水、结晶型的5-氯-3-(2-噻吩甲酰)-2-羟基吲哚-1-甲酰胺的钠盐的方法
JPH045038B2 (instruction)
RU2319706C2 (ru) Способ получения натриевой соли 3-пиридил-1-гидроксиэтилиден-1,1-бисфосфиновой кислоты (ризедроната) в кристаллической полупятиводной форме (варианты)
JPH07504892A (ja) グリセロホスホコリンの製造のための結晶化方法
JPH0643429B2 (ja) 高度に結晶性のナトリウムセフオペラゾンの製法
AU745058B2 (en) Method of purifying carbazole ester precursors of 6-chloro-alpha-methyl-carbazole-2-acetic acid
US3932386A (en) Sodium 6-(L-aminocyclohexane carboxamido)penicillanic acid
US2764612A (en) Process for preparing salts of glutamic acid
JP2907520B2 (ja) 界面活性剤の製造方法
US3041345A (en) Process of preparation of isonicotinyl hydrazones and hydrazides
KR960000359B1 (ko) 세포페라존 나트륨의 제조방법
SU487896A1 (ru) Способ получени пирофосфоновых кислот
SU833250A1 (ru) Способ получени -д-маннозы
NO171111B (no) Fremgangsmaate til fremstilling av en ny krystallmodifikasjon av dinatrium-3-amino-1-hydroksypropan-1,1-difosfonat
JPS5838429B2 (ja) Ｎ−ベンジルオキシカルボニルアスパラギン酸の純化方法
HK1023999B (en) METHOD OF PURIFYING CARBAZOLE ESTER PRECURSORS OF 6-CHLORO-α-METHYL-CARBAZOLE-2-ACETIC ACID
JPS61251695A (ja) 糖脂肪酸エステルの精製法
HK1028037A (en) An improved process for preparing 4-amino-1,2,4-triazolin-5-ones
NO168298B (no) Fremgangsmaate for fremstilling av meso 2,5-dihalogenadipater

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20050729